Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
News|Articles|January 15, 2025
Key Drugs to Watch for Community Pharmacy in 2025
Author(s)Luke Halpern, Associate Editor
These drugs are set to revolutionize their respective disease states in 2025.
Advertisement
Advertisement
Each year, dozens of new drugs are launched and enter the market, offering countless patients’ new therapeutic options for a multitude of common diseases and conditions, such as in diabetes management, dermatitis, or infectious disease control. For 2025, experts from Clarivate compiled a series of drugs that are poised to significantly transform their indicated disease states in the coming year and beyond.1
Related to this article
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Advertisement
Advertisement